Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung CancerAlexander Drilon, Vivek Subbiah, Nir Peled et al.|New England Journal of Medicine|2020Cited by 835
Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer ModelingJuliann Chmielecki, William Pao, Jasmine Foo et al.|Science Translational Medicine|2011Cited by 530
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor <i>BRAF</i> gene mutations but lack mutations in <i>KRAS, NRAS,</i> or <i>MEK1</i>Kadoaki Ohashi, William Pao|Proceedings of the National Academy of Sciences|2012Cited by 436
PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung CancersAlexander Drilon, Kristoffer Staal Rohrberg, Geoffrey R. Oxnard et al.|Journal of Thoracic Oncology|2019Cited by 81
Induction of lung adenocarcinoma in transgenic mice expressing activated <i>EGFR</i> driven by the SP‐C promoterKadoaki Ohashi, Katsuyuki Kiura|Cancer Science|2008Cited by 28